Tardive dyskinesia (TD) is a side effect of chronic antipsychotic medication exposure. Abnormalities in dopaminergic activity in the nigro-striatal system have been most often suggested to be involved because the agents that cause TD share in common potent antagonism of dopamine D 2 receptors (DRD2). Thus, a number of studies have focused on the association of dopamine system gene polymorphisms and TD, with the most consistent findings being an association between TD and the Ser9Gly polymorphism of the DRD3 gene and the TaqIA site 3 0 of the DRD2 gene. The DRD4 gene codes for the third member of the D 2 -like dopamine receptor family, and the variable number tandem-repeat polymorphism in exon 3 of DRD4 has been associated with TD. However, other polymorphisms have not been thoroughly examined. In this study, we investigated five polymorphisms spanning the DRD4 gene and their association with TD in our European Caucasian sample (N ¼ 171). Although the exon 3 variable number tandem repeat was not associated with TD, haplotypes consisting of four tag polymorphisms were associated with TD in males. This study suggests that DRD4 may be involved in TD in the Caucasian population, although further replication studies are needed.
Introduction
Tardive dyskinesia (TD) is a potentially irreversible motor side effect that develops in approximately 25% of schizophrenia patients on long-term typical antipsychotic medication (reviewed by Margolese et al. 1 and Tarsy and Baldessarini 2 ). The disfiguring and sometimes disabling involuntary movements can interfere with daily functioning and treatment adherence, resulting in reduced quality of life. 3, 4 The notion that the atypical antipsychotics are the clear choice over their conventional counterparts has more recently been tempered by evidence challenging their clinical superiority, as well as growing concerns regarding the increased liability for weight gain and metabolic abnormalities associated with these newer drugs. 5, 6 Moreover, although the atypical agents may have a lower risk for TD, none are without risk. 2, [7] [8] [9] [10] Thus, TD remains a real concern in clinical practice and strategies that may assist in predicting those patients who are vulnerable remains a high priority.
Unfortunately, the etiology of TD is complex and remains unclear. Older age Caucasians, but socioeconomic factors could have contributed to these findings. Alcohol/substance abuse and smoking might further increase the risk for TD. [17] [18] [19] [20] Concordance for the presence or absence of TD among first-degree relatives has provided evidence for a genetic component as well. 21 A number of biological mechanisms have been implicated in the pathophysiology of TD. The hypothesis of hypersensitivity of dopamine receptors secondary to chronic dopamine receptor blockade by antipsychotics is one of the most popular models, as reflected by the number of genetic studies investigating dopamine system genes. [22] [23] [24] [25] [26] This hypothesis is based on several observations. Antipsychotic treatment results in persistent dyskinesia in non-human primates, with significantly decreased dopamine turnover in the caudate and substantia nigra. 27 The dopamine D 2 receptor is most densely expressed in the basal ganglia, an area of the central nervous system that regulates movements. 28 Clinical studies [29] [30] [31] [32] and rodent vacuous chewing TD models 33, 34 have shown that, compared with atypical antipsychotics, TD is more likely to develop after treatment with typical agents that generally have higher affinities for the D 2 receptor. It has been noted that antipsychotic drugs with high affinities for D 2 have a lower risk of TD, for example olanzapine, risperidone and ziprasidone, although several mechanisms have been proposed to account for this, including potent concomitant 5HT 2A antagonism 35 and rapid D 2 dissociation. 36, 37 Antipsychotic drugs with D4 affinity may protect against TD. The most notable example is clozapine with high D 4 affinity and reports of reduction of TD symptoms after starting clozapine. 38 Also the rat model of TD shows amelioration with clozapine treatment. 34 Summarizing, DNA variations in the genes coding for the D 2 -like receptors may contribute to the risk of TD development. We have previously found polymorphisms associated with genes coding for the D 2 and D 3 receptors to influence TD risk and severity.
14,39 D 4 , the other member of the D 2 -like receptor family, is expressed in the striatum, 40 and transient increases of D 4 in the caudate and putamen have been reported following lesion by 6-hydroxydopamine in neonatal rats. 41 In addition, the period of D 4 increase was correlated with a period of observed motor hyperactivity. 41 A D 4 agonist exacerbated the hyperactivity, although it was reversed with a D 4 antagonist. 42 The D 4 receptor belongs to the G-protein coupled receptor family and activates intracellular signaling by inhibiting the synthesis of cyclic AMP. DRD4, the D 4 encoding gene on chromosome 11p15.5, consists of four exons and spans approximately 6 kb ( Figure 1 ). The polymorphic repeat sequence in exon 3 43 of DRD4 has been shown to affect RNA stability in luciferase assay. 44 Specifically, the 7-repeat variant was reported to give rise to lower D 4 expression 44 and thereby weaker inhibition of cAMP synthesis 45 compared with 2-and 4-repeat variants. Four association studies have been reported between DRD4 and TD, [46] [47] [48] [49] with two noting positive results, each with a different polymorphism. However, the DRD4 association with TD could not be replicated in other studies. 46, 48, 49 In this investigation, we tested for the presence of an association between the DRD4 gene and TD, using five polymorphisms spanning the DRD4 gene. TD was assessed by means of both continuous (Abnormal Involuntary Movement Scale (AIMS)) and dichotomous (TD occurrence) measures in relatively large samples of Caucasian patients with schizophrenia.
Results

Sample characteristics
The genotype distributions of all the DRD4 gene polymorphisms in the European Caucasian samples did not deviate significantly from Hardy-Weinberg equilibrium (P40.10). An increase in frequency of TD was found in females compared with males (P ¼ 0.084), although the difference did not reach statistical significance. No significant association was found between gender and genotype frequencies ( Table 1) . As expected, we also found a significant positive correlation between AIMS scores and age (r ¼ 0.306; Po0.001). Because the DRD4 gene is situated in a chromosomal region containing CpG islands and a number of imprinted genes, we also analyzed the polymorphisms in males and females separately.
Association study of individual polymorphisms and haplotypes with TD occurrence and AIMS None of the four tested SNPs was associated with TD or AIMS scores in our Caucasian schizophrenia sample. Four-marker haplotype analysis of DRD4 showed a significant association (global P ¼ 0.056), wherein the haplotype TCCA was underrepresented in TD cases (Table 2 ) (haplotype-specific P ¼ 0.008). Carriers of this haplotype also had the lowest average total AIMS scores compared with other haplotypes (global P ¼ 0.082; haplotype-specific P ¼ 0.058). When we analyzed males and females separately, we found that the TCCA haplotype was absent in male TD cases, but present in 11 male patients without TD (global P ¼ 0.002; haplotypespecific P ¼ 0.008; Figures 2 and 3 ). We also tested the variable number tandem repeat in exon 3 of DRD4, and we did not find a significant difference in the distribution of alleles between patients with and without TD (Fisher's Exact Study of TD and DRD4 gene in schizophrenia patients
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Test P ¼ 0.862; CLUMP P ¼ 0.956; Table 1 ). Because we did not find the variable number tandem repeat to be significant as an individual marker, and to reduce the degrees of freedom, we have excluded the variable number tandem repeat from the haplotype analyses.
Copy-number variations at the DRD4 locus
Because DRD4 is located in a region with copy-number variations, we counted the number of patients homozygous for all genotyped markers and compared the frequencies between the group with TD and the group without. Runs of homozygosity may give an indication of potential hemizygosity due to deletion at the copy-number variation. We did not find a significant difference in the frequency of runs of homozygosity between the two groups (P ¼ 0.69).
Discussion
We report here about a significant association between haplotypes consisting of four markers in DRD4 and TD in our male Caucasian schizophrenia patients. Previous studies have yielded mixed results with regard to the DRD4 gene and TD, with several possible explanations. First, different polymorphisms were used in many of the studies, and in most cases only a few polymorphisms were tested without haplotype analyses. Second, populations with different ethnic backgrounds were used in the studies, making findings difficult to compare due to potential stratification effects. Further, in some studies, the sample sizes were small, limiting the power to detect an association. The aim of our study was to investigate polymorphisms spanning the DRD4 gene for association with TD in a relatively large sample involving haplotype analyses. This study encourages further examination of DRD4 haplotypes and TD, especially in males. It does not appear to be related to the variable number tandem repeat in exon 3. As DRD4 is located in a CpG island, investigating for sexspecific changes in methylation status may help illuminate a mechanism underlying the haplotypic association observed in our study. Nonetheless, our study has several limitations. First, not all clinical data were available for each patient in our study, including detailed information regarding 51-53 Moreover, we did not have information on tobacco, alcohol or substance use for our entire sample. Finally, the marginally significant association could be due to the possibility that the polymorphisms have only a small contributing effect to the risk for TD, as expected in complex phenotypes. Our reported P-values have not been corrected for multiple testing, and would not have survived correction for all of the single polymorphisms and their haplotypes. The sample size in this study had limited power to detect a significant difference in AIMS scores between the genotypes. Under reasonable assumptions (a set at 0.05, marker allele frequency set at 0.2), the sample used for this study has 80% power to detect an odds ratio of as low as 2.1. 54 If DRD4 gene is associated with TD, it is unlikely to be the only genetically determined factor, as other genes have also been associated. Genetic studies have identified DRD3, Table 2 Global P-values from sliding-window analyses of DRD4 haplotypes for association with TD occurrence using COCAPHASE, and AIMS using QTPHASE with two, three and four markers Figure 3 Haplotype analysis of the four DRD4 polymorphisms (rs3758653, rs916457, rs762502, rs11246226) with tardive dyskinesia (TD) occurrence, separately for males (top) and females (bottom). The numbers above the bars correspond to the number of patients with the respective haplotypes. DRD2, MnSOD, CYP2D6, CYP1A2, HTR2A to be reproducibly associated with TD, 39, [55] [56] [57] [58] [59] although studies in other genes, such as HTR2C, NQO1 and GABRB2, require further investigation. [60] [61] [62] As nearly all antipsychotics target more than one receptor, it is more likely that TD is not related to one receptor gene, but instead represents a polygenic condition with each gene contributing a small proportion of the risk to this disorder. Gene-gene interaction studies may help to identify and clarify pathways that contribute to TD. TD risk is also more likely to be influenced by environmental factors; 50 acquiring this information will help in increasing the statistical power and limiting the effects of potential confounders in genetic studies of TD. 63 All patients had received a cumulative treatment exposure of at least 1 year with typical antipsychotics. For the Meltzer, Lieberman and Potkin samples, the presence or absence of TD was evaluated before any atypical antipsychotic administration, although patients were on both typical and atypical antipsychotics when TD was evaluated in the Remington sample. The presence of TD was assessed using the Abnormal Involuntary Movement Scale (AIMS) or the modified Hillside Simpson Dyskinesia Scale (HSDS) for 38 patients recruited from the Hillside Hospital. [64] [65] [66] The seven body area items and the overall global item of the HSDS match those of the AIMS; thus, assessment for presence of TD was equivalent for all four sites. All four clinicians (GR, HYM, JAL, SGP) are highly experienced in TD severity measurements, and consistency was further enhanced by exchange visits across sites. In all, 171 Caucasian patients were studied and AIMS scores were available for 144 patients, of which 70 were positive for TD.
Materials and methods
Patients
Gene polymorphism analysis
Genomic DNA was purified from whole blood samples using high-salt method described previously. 67 Genotyping was done after the patients completed the follow-up, with all laboratory staff blind to AIMS scores. The variable number tandem-repeat polymorphism in exon 3 that changes the amino-acid sequence of the receptor protein has been used in previous TD studies [46] [47] [48] and the remaining five polymorphisms, rs3758653, rs916457, rs762502, rs11246226, rs936465, were selected based on their position within the DRD4 gene and the presence of sufficiently high minor allele frequencies with genotype information available for the Caucasian (CEU) and African (YRI) samples using single-nucleotide polymorphism (SNP) tagger on the HapMap website (www.hapmap. org 68 ). After genotyping these five polymorphisms in our own Caucasian TD sample, we ran SNP tagger on the Haploview software and rs936465 was not tagged in our sample using r 2 threshold of 0.80, and was excluded from further analysis. The remaining tag polymorphisms and their locations are shown in Figure 1 . The SNPs were genotyped using the Illumina SNP platform. 69 The exon 3 VNTR was genotyped using PCR with conditions described previously, 43 and resolved on 3% highresolution agarose gels. All ambiguous genotypes were retyped and if they remained ambiguous, they were excluded from the analysis.
Statistics
Statistical analyses were conducted using the Statistical Package for the Social Sciences version 15, Haploview version 4.0, and UNPHASED version 2.402. 68, [70] [71] [72] Odds ratio calculations were conducted using Program 2BY2 version 2 written by Jurg Ott. Genotype frequency distribution was tested for fitness to Hardy-Weinberg equilibrium using Haploview. The association of genotype frequencies with age and AIMS scores was assessed using analysis of variance, and where the variances of AIMS scores among genotypes differed significantly using the Levene Test for homogeneity of variance, AIMS scores were examined with the Kruskal-Wallis test on SPSS. Gender differences in genotype frequencies were assessed using the w 2 -test on SPSS. The differences in allele and genotype frequencies between patients with and without TD were analyzed by w 2 -test. For contingency tables with at least one expected cell count of less than five, two-tailed Fisher's Exact Tests were performed (http://home.clara.net/sisa/fiveby2.htm). Haplotype analyses and linkage disequilibrium calculations were conducted using UNPHASED and Haploview, respectively. The exon 3 VNTR was analyzed with Fisher's Exact Test, and the Monte Carlo test in CLUMP. 73 
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